CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Favipiravir + Standard of CareWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)

Name (Synonyms) Correlation
drug1211 Inhaled nitric oxide gas Wiki 1.00
drug2319 Standard of Care Wiki 0.20

Correlated MeSH Terms (5)

Name (Synonyms) Correlation
D003428 Cross Infection NIH 0.58
D003141 Communicable Diseases NIH 0.09
D007239 Infection NIH 0.06
D045169 Severe Acute Respiratory Syndrome NIH 0.05
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 Open Label, Randomized, Controlled Phase 2 Proof-of-Concept Study of the Use of Favipiravir v. Standard of Care in Hospitalized Subjects With COVID-19

To determine the effect of favipiravir + SOC v. SOC on COVID-19 viral clearance.

NCT04358549 COVID-19 Drug: Favipiravir + Standard of Care Drug: Standard of Care

Primary Outcomes

Description: To determine the effect of favipiravir + SOC v. SOC on viral clearance of COVID-19 as measured by nasopharyngeal and oropharyngeal sampling

Measure: Time to viral clearance

Time: Day 29

Secondary Outcomes

Description: To determine the clinical benefit of administering favipiravir plus SOC compared to SOC alone, clinical benefit will be measured using a study-specified ordinal scale on Day 15 in adult patients hospitalized with COVID-19.

Measure: Status of clinical recovery as measured by the study-specific 6-point ordinal scale on Day 15

Time: through Day 15

Description: The NEWS is based on a simple aggregate scoring system in which a score is allocated to physiological measurements, already recorded in routine practice, when patients present to, or are being monitored in hospital. Six simple physiological parameters form the basis of the scoring system: respiration rate, oxygen saturation, systolic blood pressure, pulse rate, level of consciousness or new confusion, temperature.

Measure: Clinical effect of favipiravir + SOC compared to SOC measured by the National Early Warning Score 2 (NEWS2)

Time: through Day 29

Description: Measurement of maximum plasma concentration

Measure: Characterize the pharmacokinetics (PK) of favipiravir in plasma: Cmax)

Time: through Day 14

Description: Measurement of minimum plasma concentration

Measure: Characterized the pharmacokinetics (PK) of favipiravir in plasma: Cmin

Time: through Day 14

Description: Measurement of the area under the curve of plasma concentration versus time profile

Measure: Characterized the pharmacokinetics (PK) of favipiravir in plasma: AUC

Time: through Day 14

No related HPO nodes (Using clinical trials)